NAMS Menopause Certification Comprehensive Exam Review
2026/ 2027 | Verified Practice Q&A with Rationales
Question 1
Which of the following hormonal markers is the earliest reliable
indicator of declining ovarian reserve during the menopausal
transition?
• A. Follicle-Stimulating Hormone (FSH)
• B. Anti-Müllerian Hormone (AMH)
• C. Inhibin B
• D. Estradiol
Correct Answer: B. Anti-Müllerian Hormone (AMH)
Detailed Rationale: Anti-Müllerian hormone is produced by granulosa
cells of preantral and small antral follicles. It declines steadily with age
and represents the earliest quantitative marker of diminishing ovarian
reserve, often dropping before changes are seen in FSH or estradiol
levels.
Question 2
Which neurochemical pathway is now known to play a primary role in
triggering vasomotor symptoms (hot flashes) through the
thermoregulatory zone of the hypothalamus?
• A. Dopaminergic pathway via D2 receptors
, • B. Cholinergic pathway via muscarinic receptors
• C. Neurokinin B signaling via KNDy neurons
• D. GABAergic inhibition of the amygdala
Correct Answer: C. Neurokinin B signaling via KNDy neurons
Detailed Rationale: Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
in the infundibular nucleus of the hypothalamus undergo hypertrophy
and hyperactivation in estrogen-deficient states, leading to
inappropriate activation of the thermoregulatory zone and triggering
vasomotor symptoms.
Question 3
When prescribing systemic menopausal hormone therapy (MHT), which
of the following delivery routes is associated with a significantly lower
risk of venous thromboembolism (VTE)?
• A. Oral conjugated equine estrogens
• B. Transdermal 17-beta estradiol patch
• C. Oral synthetic ethinyl estradiol
• D. High-dose oral micronized estradiol
Correct Answer: B. Transdermal 17-beta estradiol patch
Detailed Rationale: Transdermal estradiol bypasses hepatic first-pass
metabolism, meaning it does not alter hepatic synthesis of clotting
factors and coagulation proteins in the same manner as oral estrogen,
resulting in a neutral or substantially lower risk of VTE.
Question 4
,What is the recommended first-line treatment for a postmenopausal
patient presenting with symptomatic genitourinary syndrome of
menopause (GSM) characterized by moderate vaginal dryness and
dyspareunia without systemic symptoms?
• A. Systemic oral estrogen therapy
• B. Low-dose vaginal estrogen therapy
• C. Oral selective estrogen receptor modulators
• D. Systemic transdermal hormone therapy
Correct Answer: B. Low-dose vaginal estrogen therapy
Detailed Rationale: For women whose symptoms are purely localized to
the genitourinary tract (GSM), low-dose vaginal estrogen therapy is the
preferred first-line treatment because it provides direct tissue relief
with minimal systemic absorption.
Question 5
According to current clinical guidelines, what is the diagnostic definition
of premature ovarian insufficiency (POI)?
• A. Cessation of menses for 6 consecutive months before age 45
with elevated FSH levels
• B. Cessation of menses for 4 consecutive months before age 50
with normal FSH levels
• C. Cessation of menses for 12 consecutive months before age 40
with elevated FSH levels in the menopausal range
• D. Irregular menstrual cycles and vasomotor symptoms before age
35 with low AMH only
, Correct Answer: C. Cessation of menses for 12 consecutive months
before age 40 with elevated FSH levels in the menopausal range
Detailed Rationale: POI is defined as oligo/amenorrhea for at least 4 to
6 months (though clinical confirmation often requires 12 months or
documented ovarian failure) occurring before the age of 40,
accompanied by elevated gonadotropin levels (FSH) into the
menopausal range on two occasions at least one month apart.
Question 6
Fezolinetant is a non-hormonal pharmaceutical agent approved for the
management of moderate-to-severe vasomotor symptoms associated
with menopause. What is its mechanism of action?
• A. Selective serotonin reuptake inhibition
• B. Neurokinin 3 (NK3) receptor antagonist
• C. Gamma-aminobutyric acid receptor agonist
• D. Alpha-2 adrenergic receptor agonist
Correct Answer: B. Neurokinin 3 (NK3) receptor antagonist
Detailed Rationale: Fezolinetant is a selective neurokinin 3 (NK3)
receptor antagonist that blocks neurokinin B binding in the
thermoregulatory center, effectively calming hyperactive KNDy neurons
and reducing the frequency and severity of hot flashes.
Question 7
What is the diagnostic T-score threshold on a dual-energy X-ray
absorptiometry (DEXA) scan that defines osteoporosis in
postmenopausal women?
2026/ 2027 | Verified Practice Q&A with Rationales
Question 1
Which of the following hormonal markers is the earliest reliable
indicator of declining ovarian reserve during the menopausal
transition?
• A. Follicle-Stimulating Hormone (FSH)
• B. Anti-Müllerian Hormone (AMH)
• C. Inhibin B
• D. Estradiol
Correct Answer: B. Anti-Müllerian Hormone (AMH)
Detailed Rationale: Anti-Müllerian hormone is produced by granulosa
cells of preantral and small antral follicles. It declines steadily with age
and represents the earliest quantitative marker of diminishing ovarian
reserve, often dropping before changes are seen in FSH or estradiol
levels.
Question 2
Which neurochemical pathway is now known to play a primary role in
triggering vasomotor symptoms (hot flashes) through the
thermoregulatory zone of the hypothalamus?
• A. Dopaminergic pathway via D2 receptors
, • B. Cholinergic pathway via muscarinic receptors
• C. Neurokinin B signaling via KNDy neurons
• D. GABAergic inhibition of the amygdala
Correct Answer: C. Neurokinin B signaling via KNDy neurons
Detailed Rationale: Kisspeptin/neurokinin B/dynorphin (KNDy) neurons
in the infundibular nucleus of the hypothalamus undergo hypertrophy
and hyperactivation in estrogen-deficient states, leading to
inappropriate activation of the thermoregulatory zone and triggering
vasomotor symptoms.
Question 3
When prescribing systemic menopausal hormone therapy (MHT), which
of the following delivery routes is associated with a significantly lower
risk of venous thromboembolism (VTE)?
• A. Oral conjugated equine estrogens
• B. Transdermal 17-beta estradiol patch
• C. Oral synthetic ethinyl estradiol
• D. High-dose oral micronized estradiol
Correct Answer: B. Transdermal 17-beta estradiol patch
Detailed Rationale: Transdermal estradiol bypasses hepatic first-pass
metabolism, meaning it does not alter hepatic synthesis of clotting
factors and coagulation proteins in the same manner as oral estrogen,
resulting in a neutral or substantially lower risk of VTE.
Question 4
,What is the recommended first-line treatment for a postmenopausal
patient presenting with symptomatic genitourinary syndrome of
menopause (GSM) characterized by moderate vaginal dryness and
dyspareunia without systemic symptoms?
• A. Systemic oral estrogen therapy
• B. Low-dose vaginal estrogen therapy
• C. Oral selective estrogen receptor modulators
• D. Systemic transdermal hormone therapy
Correct Answer: B. Low-dose vaginal estrogen therapy
Detailed Rationale: For women whose symptoms are purely localized to
the genitourinary tract (GSM), low-dose vaginal estrogen therapy is the
preferred first-line treatment because it provides direct tissue relief
with minimal systemic absorption.
Question 5
According to current clinical guidelines, what is the diagnostic definition
of premature ovarian insufficiency (POI)?
• A. Cessation of menses for 6 consecutive months before age 45
with elevated FSH levels
• B. Cessation of menses for 4 consecutive months before age 50
with normal FSH levels
• C. Cessation of menses for 12 consecutive months before age 40
with elevated FSH levels in the menopausal range
• D. Irregular menstrual cycles and vasomotor symptoms before age
35 with low AMH only
, Correct Answer: C. Cessation of menses for 12 consecutive months
before age 40 with elevated FSH levels in the menopausal range
Detailed Rationale: POI is defined as oligo/amenorrhea for at least 4 to
6 months (though clinical confirmation often requires 12 months or
documented ovarian failure) occurring before the age of 40,
accompanied by elevated gonadotropin levels (FSH) into the
menopausal range on two occasions at least one month apart.
Question 6
Fezolinetant is a non-hormonal pharmaceutical agent approved for the
management of moderate-to-severe vasomotor symptoms associated
with menopause. What is its mechanism of action?
• A. Selective serotonin reuptake inhibition
• B. Neurokinin 3 (NK3) receptor antagonist
• C. Gamma-aminobutyric acid receptor agonist
• D. Alpha-2 adrenergic receptor agonist
Correct Answer: B. Neurokinin 3 (NK3) receptor antagonist
Detailed Rationale: Fezolinetant is a selective neurokinin 3 (NK3)
receptor antagonist that blocks neurokinin B binding in the
thermoregulatory center, effectively calming hyperactive KNDy neurons
and reducing the frequency and severity of hot flashes.
Question 7
What is the diagnostic T-score threshold on a dual-energy X-ray
absorptiometry (DEXA) scan that defines osteoporosis in
postmenopausal women?
